Read by QxMD icon Read

Keppra, levetiracetam

M Trimboli, E Russo, L Mumoli, G Tripepi, F Fortunato, G Mastroianni, F Abate, G De Sarro, A Gambardella, A Labate
BACKGROUND AND PURPOSE: The purpose of this study was to determine whether switching from branded levetiracetam (Keppra® ) to a levetiracetam generic equivalent product (Matever® ) in an epilepsy cohort could provide adequate results in terms of seizure control and tolerability. METHODS: To be eligible for the study, patients had to have been taking Keppra® as monotherapy or polytherapy for at least 6 months. Between March 2013 and April 2017, patients were invited to switch to Matever® as part of their follow-up...
April 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Martina Fanella, Alessandra Morano, Jinane Fattouch, Mariarita Albini, Luca M Basili, Sara Casciato, Mario Manfredi, Anna T Giallonardo, Carlo Di Bonaventura
OBJECTIVES: Generic antiepileptic drugs represent a measure to maximize cost saving. Levetiracetam (LEV) is one of most commonly used and effective antiepileptic drugs. The objective of our work was to demonstrate the effectiveness and safety of overnight switch from monotherapy with Keppra (original drug) to epitiram (generic drug) at the same dose. METHODS: In our observational study, we consecutively enrolled 37 seizure-free patients with epilepsy who expressed the wish to switch to a generic drug for economic reasons...
November 2017: Clinical Neuropharmacology
Anna Elizabeth Sutherland, John Curtin, Victoria Bradley, Olivia Bush, Maggie Presswood, Victoria Hedges, Katrien Naessens
OBJECTIVES: To report the results of a combined case series analysis of subcutaneous levetiracetam (Keppra) for the management of seizures in palliative care patients. METHODS: A comprehensive literature review on the use of subcutaneous levetiracetam was performed, and these data were combined with a prospective observational audit of its use in terminal care undertaken in a regional palliative care network. RESULTS: 7 papers were identified from the literature review-four case reports and three observational case series-reporting on a total of 53 cases where subcutaneous levetiracetam was administered...
July 22, 2017: BMJ Supportive & Palliative Care
Arne Reimers, Patrik Olsson, Johanna Nilsson, Elin Hoff, Margareta Reis, Maria Strandberg, Anders Lundgren, Kristina Källén
BACKGROUND: Switching patients from a branded antiepileptic drug (AED) to a generic is often challenging. Several studies have shown that considerable proportions of patients report deteriorated seizure control or increased adverse effects, enforcing a switchback to the original drug. Since tolerability and seizure control usually correlate with AED serum concentrations, we examined the fluctuation of levetiracetam (LEV) serum concentrations in patients with epilepsy before and after generic substitution...
August 2017: Epilepsy Research
Rebecca P Haberman, Audrey Branch, Michela Gallagher
Sporadic late-onset Alzheimer's disease (LOAD), the most common form of dementia in the elderly, causes progressive and severe loss of cognitive abilities. With greater numbers of people living to advanced ages, LOAD will increasingly burden both the healthcare system and society. There are currently no available disease-modifying therapies, and the failure of several recent pathology-based strategies has highlighted the urgent need for effective therapeutic targets. With aging as the greatest risk factor for LOAD, targeting mechanisms by which aging contributes to disease could prove an effective strategy to delay progression to clinical dementia by intervention in elderly individuals in an early prodromal stage of disease...
July 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
Sofia Markoula, Dimitrios Chatzistefanidis, Stylianos Gatzonis, Anna Siatouni, Eleftheria Siarava, Anastasia Verentzioti, Athanassios P Kyritsis, Philip N Patsalos
PURPOSE: The therapeutic equivalence of generic and brand antiepileptic drugs, based on studies performed on healthy volunteers, has been questioned. We compare, in a routine clinical setting, brand versus generic levetiracetam (LEV) bioequivalence in patients with epilepsy and also the clinical efficacy and tolerability of the substitution. METHODS: A prospective, open-label, non-randomized, steady-state, multiple-dose, bioequivalence study was conducted in 12 patients with epilepsy (5 females), with a mean age of 38...
May 2017: Seizure: the Journal of the British Epilepsy Association
A Schattner, A Al-Bewerat
No abstract text is available yet for this article.
October 2016: Netherlands Journal of Medicine
Sara Sanz-Blasco, Juan C Piña-Crespo, Xiaofei Zhang, Scott R McKercher, Stuart A Lipton
A recently identified mechanism for oligomeric Aβ-induced glutamate release from astrocytes involves intracellular Ca elevation, potentially by Ca-dependent vesicular release. Evidence suggests that levetiracetam (LEV; Keppra), an antiepileptic drug, can improve cognitive performance in both humans with mild cognitive impairment and animal models of Alzheimer disease. Because LEV acts by modulating neurotransmitter release from neurons by interaction with synaptic vesicles, we tested the effect of LEV on Aβ-induced astrocytic release of glutamate...
June 15, 2016: Neuroreport
Sophie Boudriau, Cecilia Hanzel, Julie Massicotte, Laura Sayegh, Jing Wang, Marc Lefebvre
BACKGROUND: Rapidly disintegrating or 'fast-melt' oral formulations have been developed recently to facilitate drug intake among patients. Even though these formulations have helped to improve therapy adherence, some of their limitations include: the dissolution time, their facility to be swallowed, and the dosage strengths that may be accommodated. To overcome these limitations, a novel, porous, quickly disintegrating, and easier-to-swallow fast-melt formulation based on powder-liquid, three-dimensional printing (3DP) technology has been developed...
June 2016: Drugs in R&D
Tal Lavi-Blau, Dana Ekstein, Miri Y Neufeld, Sara Eyal
Surveys among women with epilepsy (WWE) show that they receive their essential pregnancy-related information from many sources, including the internet. Our aim was to assess the types of websites provided by searching Google for the use of four antiepileptic drugs (AEDs) during pregnancy and lactation. The search was performed on 40 computers used by health-care professionals, on 40 computers used by nonhealth-care professionals, and on 5 computers used by WWE in Israel and on 8 computers used by nonhealth-care professionals in the U...
February 2016: Epilepsy & Behavior: E&B
Gail D Anderson, Russell P Saneto
Modified-release or extended-release (XR) formulations are used to decrease the frequency of dosing for drugs with rapid elimination, to improve convenience and adherence. Use of a modified-release formulation can decrease the peak to trough fluctuations in serum concentrations and theoretically improve the therapeutic benefit of the drug, by decreasing adverse events associated with the higher peak concentrations. Once-daily formulations of lamotrigine (Lamictal XR(®)), levetiracetam (Keppra XR(®)), oxcarbazepine (Oxtellar XR(®), Apydan(®) extent) and topiramate (Qudexy XR™, Trokendi XR™) are approved for the treatment of focal and/or generalized onset seizures...
August 2015: CNS Drugs
Vivek Ramakrishnan, Robert Dahlin, Omid Hariri, Syed A Quadri, Saman Farr, Dan Miulli, Javed Siddiqi
BACKGROUND: Seizures account for significant morbidity and mortality early in the course of traumatic brain injury (TBI). Although there is sufficient literature suggesting short-term benefits of antiepileptic drugs (AEDs) in post-TBI patients, there has been no study to suggest a time frame for continuing AEDs in patients who have undergone a decompressive craniectomy for more severe TBI. We examined trends in a level-II trauma center in southern California that may provide guidelines for AED treatment in craniectomy patients...
2015: Surgical Neurology International
Ekokobe Fonkem, Paul Bricker, Diana Mungall, Jose Aceves, Eromata Ebwe, Wei Tang, Batool Kirmani
Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is being increasingly used in brain tumor patients. In patients suffering with brain tumors, seizures are one of the leading neurologic complications being seen in more than 30% of patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemotherapy or other drugs that induce cytochrome P450, causing significant drug interactions...
October 7, 2013: Frontiers in Neurology
Wenxia Luo, Sing Teang Kong, Shili Yang, Bernice Choi Wai Chan, Paul C Ho
BACKGROUND: A simple LC-MS/MS method was developed and validated for the quantification of levetiracetam (LEV, Keppra®), a broad-spectrum antiepileptic drug (AED) in rat dried blood spots (DBS). LEV was simply extracted with methanol spiked with adenosine (ADE) as IS before LC-MS/MS analysis. The correlation between the DBS and plasma concentrations of LEV was also determined. RESULTS: Linearity was from 0.067-60 µg/ml for LEV in DBS samples. The intra- and inter-day accuracy and precision of the assay met validation acceptance criteria...
August 2013: Bioanalysis
Nathalie Toublanc, Brigitte D Lacroix, Junichi Yamamoto
  Levetiracetam [E Keppra(®)] is a second generation antiepileptic drug for different types of epilepsy in adults and children ≥1 month. The objective is to develop a population pharmacokinetic model to describe the pharmacokinetics of levetiracetam in Japanese children and adults as well as North American children, the purpose being to explore potential dosing recommendations in Japanese children. Levetiracetam plasma concentration-time data were obtained from Japanese adult and pediatric clinical studies...
2014: Drug Metabolism and Pharmacokinetics
Hasan H Sonmezturk, Nabil J Azar
Extended release (XR) formulation of levetiracetam (LEV) is approved by the Food and Drug Administration as an add-on to other antiepileptic drugs (AEDs) for adults with partial onset seizures. This is based on class-I evidence demonstrating significant seizure reduction in once daily dosing. Keppra-XR is marketed with the brand name of Keppra XR since 2008 (UCB Pharma). Its original immediate release (IR) formulation has been in the market since 2000. LEV has a unique molecular structure which is chemically unrelated to existing AEDs...
2011: Journal of Central Nervous System Disease
A Kh Magomedova, M M Magomedov, A M Magomedova, M F Magomaev
No abstract text is available yet for this article.
2012: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Sandra C Bishop-Freeman, Nina C Kornegay, Ruth E Winecker
Levetiracetam (Keppra®) is one of the newer anticonvulsant drugs used to treat seizures. Since 2003, the North Carolina Office of the Chief Medical Examiner Toxicology Laboratory has collected quantitative levetiracetam data in samples for 56 postmortem cases. The data presented herein will provide the forensic community with concentrations to assist in the interpretation of levetiracetam in postmortem blood. Decedents were divided into two groups according to manner of death as determined by the medical examiner for the purposes of studying levetiracetam concentrations...
July 2012: Journal of Analytical Toxicology
S O Aĭvazian, Iu S Shiriaev
The objective was to retrospectively study the efficacy and safety of levetiracetam (keppra) as an add-on treatment of pharmacoresistant forms of epilepsy in children. We have analyzed medical histories of 192 patients with pharmacoresistant epilepsy admitted to a neurological department of the Research and Treatment Center of Children's Medical Care over the period of 2008-2011. The patient's age varied in the range from 6 months to 19 years (mean age 5.7 years). The results of the study revealed the high efficacy of levetiracetam as an add-on treatment of pharmacoresistant epilepsy in children...
2011: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Takuro Hayashi, Koji Inoue, Jun Shinoda
Levetiracetam (brand name: E Keppra®) is a new antiepileptic drug marketed in Japan since 2010 1, 2). Clinical reports of its use in Japan are few. Our experience with levetiracetam in a patient with secondarily generalized seizures yielded interesting findings. The patient was a 62-year-old man receiving 4 antiepileptic drugs and 9 psychotropic drugs for treatment of secondarily generalized seizures (due to a cerebral contusion that occurred 20 years ago) and associated depressive symptoms, mainly anxiety and insomnia...
March 2012: Brain and Nerve, Shinkei Kenkyū No Shinpo
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"